NEW TAIPEI CITY, Taiwan, March 23, 2026 /PRNewswire/ -- GlycoNex, Inc. (4168, hereinafter referred to as GNX), a clinical-stage biotechnology company focused on the development of glycan-directed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results